NCT02581592View on ClinicalTrials.gov

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Hepatic Impairment

Interventions

DRUG

TD-4208

A single inhaled dose of TD 4208 (175 mcg)

Trial Locations (1)

32809

Orlando Clinical Research Center (OCRD), Orlando

Sponsors

Lead Sponsor

Collaborators (1)

Theravance Biopharma

All Listed Sponsors

collaborator

Theravance Biopharma

INDUSTRY

lead

Mylan Inc.

INDUSTRY